Earnings ·
AgomAb Therapeutics NV reported financial results for the six months ended June 30, 2026, and confirmed its business…
AGMBAgomAb Therapeutics NV
AgomAb Therapeutics NV reported financial results for the six months ended June 30, 2026, and confirmed its business outlook. The company achieved a cash position of €252 million as of June 30, 2026, including $208 million in gross proceeds from its February 2026 IPO, which extends the cash runway into the first half of 2029. Research and development expenses were €23.0 million, while general and administrative expenses rose to €12.2 million due to one-off IPO costs. The net loss for the period was €31.0 million compared to €26.9 million in the prior year period. Clinically, AgomAb aligned with the FDA on the design of the NOV-ERA Phase 2b study for ontunisertib in Fibrostenosing Crohn’s Disease and expects to initiate this trial in the second half of 2026. Topline data from the long-term extension study of ontunisertib and a Phase 1b cohort with AGMB-447 in Idiopathic Pulmonary Fibrosis are expected in the coming months. AgomAb is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases.